Murphy & Mullick Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Murphy & Mullick Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.8K	Hold	165	–	–	0.04%	279
2026 Q1	$21.1K	Hold	165	–	–	0.02%	391
2025 Q4	$20.1K	Hold	165	–	–	0.01%	399
2025 Q3	$18.5K	Hold	165	–	–	0.01%	396
2025 Q2	$13.7K	Hold	165	–	–	0.01%	416
2025 Q1	$13.4K	Hold	165	–	–	0.01%	400
2024 Q4	$14.9K	Buy	+165	New	+$16K	0.01%	393

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Murphy & Mullick Capital Management's XBI Position: Q2 2026 in Review

Murphy & Mullick Capital Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 165 shares worth $57.8K. The position accounts for 0.04% of the portfolio, ranked #279.

Murphy & Mullick Capital Management first reported a position in XBI in Q4 2024 and has held it in 7 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Murphy & Mullick Capital Management held 165 shares of State Street SPDR S&P Biotech ETF worth $57.8K as of Q2 2026.
Murphy & Mullick Capital Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.04% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #279 holding.
Murphy & Mullick Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 7 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.